37 results about "Maternal fetal" patented technology

A maternal-fetal monitoring system for use during all stages of pregnancy, including antepartum and intrapartum stages. The maternal-fetal monitoring system of the subject invention comprises (1) a set of sensors; (2) an amplifying / filtering means; (3) a computing means; and (4) a graphical user interface. Accurate clinical data, which can be extracted and provided to the user in real-time using the system of the invention, include without limitation, maternal electrocardiogram (ECG) signals, maternal uterine activity signals (EHG), maternal heart rate, fetal ECG signals, and fetal heart rate. In a preferred embodiment, the maternal-fetal monitoring system of the invention includes an intelligence means, such as a neural network system, to analyze and interpret clinical data for use in clinical diagnosis antepartum, intrapartum and postpartum, as well as delivery strategy.

A maternal-fetal monitoring system for use during all stages of pregnancy, including antepartum and intrapartum stages. The maternal-fetal monitoring system of the subject invention comprises (1) a set of sensors; (2) an amplifying / filtering means; (3) a computing means; and (4) a graphical user interface. Accurate clinical data, which can be extracted and provided to the user in real-time using the system of the invention, include without limitation, maternal electrocardiogram (ECG) signals, maternal uterine activity signals (EHG), maternal heart rate, fetal ECG signals, and fetal heart rate. In a preferred embodiment, the maternal-fetal monitoring system of the invention includes an intelligence means, such as a neural network system, to analyze and interpret clinical data for use in clinical diagnosis antepartum, intrapartum and postpartum, as well as delivery strategy.

A maternal-fetal monitoring system for use during all stages of pregnancy, including antepartum and intrapartum stages. The maternal-fetal monitoring system of the subject invention comprises (1) a set of sensors; (2) an amplifying / filtering means; (3) a computing means; and (4) a graphical user interface. Accurate clinical data, which can be extracted and provided to the user in real-time using the system of the invention, include without limitation, maternal electrocardiogram (ECG) signals, maternal uterine activity signals (EHG), maternal heart rate, fetal ECG signals, and fetal heart rate. In a preferred embodiment, the maternal-fetal monitoring system of the invention includes an intelligence means, such as a neural network system, to analyze and interpret clinical data for use in clinical diagnosis antepartum, intrapartum and postpartum, as well as delivery strategy.

The present invention concerns a global maternal serum proteome map and its changes during healthy gestation. Accordingly, the present invention provides an important tool for plasma-based maternal-fetal diagnostics.

The invention relates to an in-vivo pulse, pulse waveform or blood pressure detector, a heart rate, heart sound, maternal fetal sound, lung breath sound or electrocardiosignal detector, an in-vivo internal organ or internal tissue image detector and the like, in particular to an electronic detector comprising a wearable part; the wearable part is provided with a sensing device at least; the wearable part is suitable for being put around or on an in-vivo limb; the wearable part comprises an electric telescopic device, an electric expansible device or an electric swinging device; the force of contact of the sensing device upon the surface of the in-vivo skin is adjusted through the electric telescopic device, the electric expansible device or the electric swinging device, or the length of the wearable part is adjusted through the electric telescopic device, the electric expansible device or the electric swinging device, thereby allowing detection.

Methods, systems, and apparatus are provided for determining zygosity of a multiple-fetus pregnancy using a biological sample taken from the mother. The fetal and maternal DNA in the sample (e.g. plasma) can be analyzed for a particular chromosomal region to identify genetic differences in the fetuses. For example, a normalized parameter for the measure of a primary or secondary allele can show variances for different chromosomal regions when fetuses are dizygotic. Such a variance can be determined relative to an expected value if the fetuses were genetically identical. Statistical methods are provided for analyzing the variation of the normalized parameters to determine fetal DNA concentration and the maternal-fetal mixed genotype at various loci. Parental genotype and haplotype information can also be used to identify inheritance of different parental haplotypes to indicate genetic differences among the fetuses.

The wearable dynamic mother fetal ECG monitor comprises an ECG signal detection module for collecting an ECG signal of a pregnant woman and connected with an analog to digital conversion module, a microprocessor, a data storage card for storing the pregnant woman ECG signal and storing the generated maternal fetal electrocardiogram information bar according to the preset storage frequency, and a wireless communication module for wirelessly transmitting the generated maternal fetal electrocardiogram information bar to a hospital or a monitoring center; the analog to digital conversion module, the data storage card and the wireless communication module are connected to the microprocessor; the microprocessor is used for real-time analysis of ECG signals, data storage and communication control, completing ECG signal quality assessment, maternal ECG signal processing, fetal ECG signal processing and generation of the maternal fetal ECG information bar. The wearable dynamic mother fetal ECGmonitor can realize dynamic, long-range monitoring and real-time analysis and processing of maternal and fetal ECG signals, and can remotely monitor the maternal and fetal ECG.

The invention relates to a maternal fetal blood group incompatibility antibody adsorption therapeutic apparatus in the field of medical science. The therapeutic apparatus is characterized in that Rh positive O-shaped red blood cells are cleaned by 4 DEG C and 37 DEG C normal saline and alternately washed by 25 and 35mmol / L of PB lysate with PH (potential of hydrogen) 7.4, D antigen containing ghost cells without hemoglobin are prepared, 80% cell concentration is formed by the aid of red blood cell storage solution with 3.5% mannitol, the ghost cells are placed in a cylindrical adsorber made of high-biocompatibility materials, sealed and stored at the temperature of 4 DEG C, and a screen is arranged at an outlet of the adsorber to form a defense line for preventing cell fragments from filtration. After plasma is filtered, Rh antibodies are combined into fixed complexes by the Rh positive red blood cells, the broken red blood cell fragments and macromolecular complexes formed by combination are intercepted by the screen of the adsorber, the plasma without morbid substances is filtered from the adsorber and then returned, and group incompatibility is treated by removing the Rh antibodies in the plasma.

The invention provides an application of decidua NK cells and cell subsets thereof in preparation of medicines for treating infertility related diseases. Through experimental verification, according to the decidua NK cell and the cell subset thereof, endometrial growth disorder diseases are treated by promoting endometrial thickness increase, enhancing endometrial cell viability, reducing endometrial cell damage, promoting VEGF expression, maintaining endometrial stromal cell dryness and stimulating proliferation; the pregnancy success rate of endometrial injury model mice is increased from 30% to 60-70%; by exerting the immune tolerance effect, reducing the spontaneous abortion rate and improving the T helper lymphocyte level to treat maternal fetal immune tolerance disorder related diseases, a new way is provided for treatment of infertility.

The invention relates to a maternal-fetal Rh blood group incompatibility immune adsorption therapeutic instrument. The maternal-fetal Rh blood group incompatibility immune adsorption therapeutic instrument is characterized in that using Rhesus monkey red blood cells to replace human Rh positive O-shaped red blood cells, washing the Rhesus monkey red blood cells with normal saline at the temperature of 4 DEG C and 37 DEG C, using 25 mmol / L PB lysis buffer having the pH of 7.4 and 35 mmol / L PB lysis buffer having the pH of 7.4 to alternatively washing the Rhesus monkey red blood cells till the upper layer is colorless, fully dialyzing harmful hemoglobin in the Rhesus monkey red blood cells, preparing Rhesus monkey blood ghost cells containing D antigen, detecting the antigenicity and installing an adsorbing device made from a high biocompatibility material, allowing the blood ghost cells to form high density compressed cell absorbing agent via repeated high-speed centrifugation, arranging screens in an inlet and an outlet of the absorbing device so as to form a defensive line for preventing filtering out of cell l debris, wherein Rh antibodies are combined with the blood ghost cells to form a fixed compound after blood plasma is filtered, the red cell solute is stopped by the screens of the absorbing device, blood plasma without morbid substances is transfused back after filtered by the absorbing device so as to treat a haemolytic disease by clearing the Rh antibodies in the blood plasma.

Provided are cytokines and methods of modulating maternal tolerance of a fetus using IL-27 agonists. Also provided are methods of modulating implantation of an embryo to a uterine lining, and methods of diagnosis.

The invention relates to an adsorption herapeutic apparatus for maternal-fetal blood group incompatibility, relating to the medical field. The apparatus is characterized by comprising following steps: utilizing PB of 25 and 35 mmol / L as lysate, fully washing Rh positive O-type erythrocytes and cleaning them with normal saline to make ghost cells with dialysis of ferrohemoglobin and antigen performance capable of effectively absorbing Rh antibodies, utilizing 0.9%, 1.0%, 1.1%, 1.2% and 1.3% of agarose which is melt at 100 DEG C and kept in 56 DEG C to make adsorbents of 95% of ghost cell concentration, orderly taking 55-65ml according to ghost cell concentration from high to low to be added into a cylindrical container made by material with high biocompatibility so that an absorber enabling adsorbents from a sample inlet end to a sample outlet end to form uniform distribution of ghost cells and agarose concentration from low to high, using the above to clear Rh anti-bodies in plasmas filtered by the absorber and macromolecule disease-causing substances generated by destroyed erythrocyte such that the treatment purpose of preventing Rh anti-bodies of pregnant women from entering fetus blood and lightening condition is achieved.

The invention relates to a therapeutic apparatus for treating a maternal-fetal blood group incompatibility-type hemolytic disease in the medical field. The therapeutic apparatus is characterized in that hemoglobin with toxic and side effects is removed from Rh-positive red blood cells through diapedesis by using PB lysate, but ghost cells which only absorb an Rh antibody and do not absorb other blood group antibodies are retained; together with an immunologically prepared anti-Rh antibody, the ghost cells are fixed to agarose with a special concentration according to a specific ratio; thereafter, the agarose is enwrapped by a cylindrical container made of a highly-biocompatible material so as to form gradually decreasing antibody valence, gradually increasing agarose concentration and uniform ghost cell distribution from a sample inlet end to a sample outlet end; near the sample outlet end, the agarose with the special concentration with gradually increasing concentration and gradually diminishing micropores can effectively intercept fragments formed after the red blood cells of a patient suffering from the hemolytic disease are destroyed, as well as macromolecular immune complexes combined with the fragments. The therapeutic apparatus provides a new toxic and side effect-free method for treating the maternal-fetal blood group incompatibility-type hemolytic disease, by which only pathogenic antibodies are removed, but plasma components are not removed.

The invention discloses an auxiliary device for abdominal version of breech-position pregnant and lying-in women. The auxiliary device comprises a first bed body and a second bed body, wherein the second bed body is arranged on one side of the first bed body; fixing plates are mounted on the two sides of the first bed body and the second bed body respectively; main fixing bands and auxiliary fixing bands are fixedly connected onto the fixing plates on the two sides respectively; limit plates are movably connected with the outer wall of one end, away from the second bed body, of the first bed body and the outer wall of one end, away from the first bed body, of the second bed body, and bolts are movably mounted on the outer walls of the limit plates. According to the auxiliary device, lengthof a treatment bed can be effectively adjusted according to body forms of the pregnant and lying-in women, by means of matching with a laser positioning device, operative positions suitable for the abdominal version of the breech-position pregnant and lying-in women are accurately set, and meanwhile, maternal-fetal damage caused by position deviation in the treatment process can be reduced by a fixing device. Besides, the back of the pregnant and lying-in women is massaged by an electric back massage device, so that muscles of the back are enabled to be relaxed, paint of the abdominal versionis relieved, and functionality of the auxiliary device is improved.

The invention discloses a traditional Chinese medicine composition for preventing ABO maternal-fetal blood group incompatibility. Infant jaundice caused by the ABO maternal-fetal blood group incompatibility mostly belongs to the scope of fetal jaundice and newborn jaundice of traditional Chinese medicine, and the key is preventive treatment during progestation and pregnancy for the infant jaundice. The composition adopts the following traditional Chinese medicines: Japanese angelica tree root bark, orchis, black soybean coat, parmelia tinctourium, thalictrum aquilegiifolium, astragalus bhotanensis, axillary choerospondias bark, dioscorea subcalva prain et bur-kill, dryland willow leaves, hempleaf negundo chastetree leaves and nothapodytes pittosporoides which are decocted by water into decoction. Clinical trials show that a total effective rate of the composition is 98%, and is obviously better than that of 70% of a control group, and the composition has a significant curative effect.

The invention discloses screening method of reference genes for fluorescent quantitative detection of caruncle mucosa of pregnant cows and application of the screening method, and relates to the technical field of animal molecular biology. Suitable reference genes are screened out for the study on gene expression of caruncle mucosa of pregnant cows; the expression of genes playing a key role uponestablishing of a bond between the maternal cow and fetus can be truly reflected; key candidate genes of maternal-fetal interaction can be further applied to assist in the important reproductive mechanisms, such as cow pregnancy establishment, pregnancy recognition, and pregnancy maintenance.

The invention belongs to the technical field of medicines, relates to application of miR-184 in early warning of spontaneous abortion and particularly relates to a method for establishing a spontaneous abortion model by intravenous injection of miR-184-3p agomir and detection of miR-184 in peripheral blood of pregnant women in early pregnancy for evaluating the risk of spontaneous abortion. Shownby in vitro experiments, high expression of miR-184 in a maternal-fetal interface in early pregnancy can induce occurrence of spontaneous abortion by a related molecular mechanism, and the expressionof miR-184 in the peripheral blood of patients with recurrent spontaneous abortion also increases; and shown by in vivo animal experiments, after intravenous injection of miR-184-3p agomir induces overexpression of miR-184 in vivo of a mouse, the absorption rate of a mouse embryo increases, thereby establishing a spontaneous abortion animal model. In addition, compared with normal pregnant women,the expression of miR184 in the peripheral blood of patients with recurrent spontaneous abortion increases, and a method for evaluating the risk of spontaneous abortion in early pregnancy is provided.

The invention relates to a maternal fetal blood group incompatibility plasma purifier in the field of medical science. The purifier is characterized in that fresh Rh positive O-shaped red blood cells are cleaned by 4 DEG C and 37 DEG C normal saline and alternately washed by 25 and 35mmol / L of PB lysate with PH (potential of hydrogen) 7.4 until an upper layer is colorless, harmful hemoglobin in the red blood cells are completely dialyzed, D antigen containing ghost cells are prepared and placed in the purifier made of high-biocompatibility materials after antigenicity is detected, the ghost cells form high-density compressed cell purifying agents after repeated high-speed centrifugation, and screens are arranged at an inlet and an outlet of the purifier to form defense lines for preventing cell fragments from filtration. After plasma is filtered, Rh antibodies are combined into fixed complexes by the ghost cells, the broken red blood cell fragments and macromolecular complexes formed by combination are intercepted by the screens of the purifier, the plasma without morbid substances is filtered from the purifier and then returned, and group incompatibility is treated by removing the Rh antibodies in the plasma.

The invention discloses screening of reference genes for quantitative PCR (polymerase chain reaction) detection of bovine reproductive system and embryo tissues and application of the screening. Suitable reference genes are screened out for the study on genetic expression of reproductive system and embryo tissues of pregnant cows; the accuracy of fluorescent quantitative PCR detection on the genetic expression of reproductive system and embryo tissues of pregnant cows is forcibly guaranteed; further study on the regulation mechanism of cow embryo development and the maternal-fetal interactionbasic law is facilitated; important theoretical support is provided for the deep understanding of related molecular mechanisms of pregnancy recognition and pregnancy establishment; theoretic basis isprovided for reducing early pregnancy failure by manual intervention means.

A person who is used in the field of medicine- Preparation of human cell fusion maternal-fetal blood group incompatibility therapy hybrid strain, characterized by, Using erythropoietin as inducer, ''O'' type human bone marrow cell positive for Rh were cultured, to increase the number of directionally developing erythroid cells, human bone marrow cells and human myeloma cells were fused into hybridized cells, Erythropoietin was use to induce that directional differentiation of the hybridized cell, Hybrid cell clones were screened by HAT, The hybridization strains of Rh positive cells which canbe expanded indefinitely in vitro were screened by Rh antibody, As that adsorbent aft industrialized amplification, A low-cost and safe method for that treatment of maternal-fetal blood group incompatibility hemolytic disease without plasma exchange solution without remove plasma and its beneficial ingredients is create by absorbing pathogenic Rh antibody in peripheral plasma of pregnant women with maternal-fetal blood group incompatibility through an in vitro adsorption device which is formed by an adsorber and a blood separator.

The invention relates to a Yin-nourishing wine for women and a production method thereof. The Yin-nourishing wine is composed of wine liquid produced by crushing shaved sow pigs into granules and soaking them in wine. Pigs are matched with 2-10 kilograms of wine. The production method includes drowning the newborn sow pigs with vinegar or wine or warm water before they eat pig milk or any food, and then scrape the sow pigs after execution. Clean all the hairs on its body, then crush the hairless sow pig into particles and put it into white wine to soak for 30-400 days, which is the step of the Yin nourishing wine. The Yin-nourishing wine has the functions of nourishing qi and blood, so that it has very good nutritional ingredients and functions such as improving immunity.

The invention relates to the technical field of biology, in particular to a tissue microarray of decidua and villi pairing, a preparation method and application thereof. The tissue microarray is prepared with the decidua and villus specimens of a normal pregnancy woman or a pathologic pregnancy patient arranged in sample application holes, so that pairing is formed between the decidua tissue and the villus tissue from the same specimen, and the functional presentation of the maternal-fetal interface of a physiological structure onto the tissue microarray is achieved. The tissue microarray has the advantages that high throughput is achieved, plenty of information is obtained in one time, and the efficiency is improved by hundreds of times; parallelization is achieved, the comparability is high, and the precision is high; the experimental error is small, and experimental conditions remain the same; convenience is brought to arrangement of various kinds of experimental control, and the research cost is greatly reduced. The tissue microarray can be used for etiology screening and molecular typing of pathologic pregnancy, screening and verifying of a novel marker, screening of individual treatment patients, judgment of a therapeutic effect and prognosis and the like, and the tissue microarray has important significance for the research of a normal pregnancy maintaining mechanism and pathologic pregnancy pathogenesis.

A person who is used in the field of medicine-Preparation of mouse cell fusion maternal-fetal blood group incompatibility therapy hybrid strain, characterized by, Using erythropoietin as inducer, ''O'' type human bone marrow cell positive for Rh were cultured, to increase the number of directionally developing erythroid cells, Then the cultured human bone marrow cells were fused with murine myeloma cells to form hybridized cells, Erythropoietin was use to induce that directional differentiation of the hybridized cell, hybrid cell clones were screened by HAT. The hybridization strains of Rh positive cells which can be expanded indefinitely in vitro were screened by Rh antibody, As that adsorbent aft industrialized amplification. A low-cost and safe method for that treatment of maternal-fetal blood group incompatibility hemolytic disease without plasma exchange solution without remove plasma and its beneficial ingredients is create by absorbing pathogenic Rh antibody in peripheral plasmaof pregnant women with maternal-fetal blood group incompatibility through an in vitro adsorption device which is formed by an adsorber and a blood separator.

The invention relates to a pharmaceutical composition for preventing or treating abortion, which is prepared from the following active components in parts by weight: 8-12 parts of angelica, 4-6 parts of white peony root, 4-6 parts of dried ginger, 1-3 parts of walnut kernel, 4-6 parts of bighead atractylodes rhizome, 6-10 parts of licorice, 8-12 parts of medlar and 1-3 parts of shiandra. After the pharmaceutical composition provided by the invention is poured into the stomach of a model rat, the pregnancy success ratio is obviously improved to 85-92%, and the litter size is obviously increased, so that the pharmaceutical composition provided by the invention can provide a favorable microenvironment for blastocyst implantation by regulation and control effects on a maternal-fetal interface endocrine-immune network, thereby maintaining pregnancy and further achieving the purpose of preventing or treating abortion.

The invention discloses a micro-fluidic chip of a multi-fetal placenta vascular anastomosis model, a system and a use method. The micro-fluidic chip comprises a chip body, a maternal fluid channel and two or more fetal fluid channels are arranged on the chip body, a porous membrane is arranged between the maternal fluid channel and the fetal fluid channels, and connecting channels which can be connected or disconnected are arranged between the fetal fluid channels. The placenta structure of multiple births such as twins or triplets is accurately and completely miniaturized and reconstructed, the placenta microstructures of two different chorionic twins can be simulated, and a replacement model can be provided for the research on the current twins / multiple birth maternal fetal barrier and the research on the potential pathophysiological mechanism of the special complications of the twins; physiological flow conditions can be simulated so as to realize blood convection motion of two fetuses of twins and a maternal body; flow conditions can be changed to simulate abnormal blood flow environments of villus gaps and fetal capillaries and changes before and after therapeutic measures are administered.

A maternal-fetal blood group incompatibility treatment device based on clearance of pathogenic antibodies for use in the medical field is characterized in that, erythropoietin is used as inducer, ''O'' type human or monkey bone marrow cell positive for Rh were cultured, to increase the number of directionally developing erythroid cells, human or monkey bone marrow cells were fused with mouse or human myeloma cells to form hybridized cells, different concentrations of erythropoietin were selected according to different fusion cells, to induce the directional differentiation of hybridized cells,Hybrid cell clones were screened by HAT, The hybridization strains of Rh positive cells which can be expanded indefinitely in vitro were screened by Rh antibody, after industrial amplification, it isused as an adsorbent to make an adsorber and then a blood separator to form an in vitro therapeutic device. By adsorbing the pathogenic Rh antibody in maternal and fetal blood group incompatible maternal plasma, a cheap and safe method for the treatment of maternal and fetal blood group incompatible hemolytic disease without removing the plasma and its beneficial ingredients is established.